Avidity Biosciences (RNA) Operating Leases (2019 - 2025)
Avidity Biosciences (RNA) has disclosed Operating Leases for 7 consecutive years, with $49.3 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Operating Leases rose 1565.57% year-over-year to $49.3 million, compared with a TTM value of $49.3 million through Dec 2025, up 1565.57%, and an annual FY2025 reading of $49.3 million, up 1565.57% over the prior year.
- Operating Leases was $49.3 million for Q4 2025 at Avidity Biosciences, down from $50.0 million in the prior quarter.
- Across five years, Operating Leases topped out at $50.0 million in Q3 2025 and bottomed at $1.2 million in Q2 2025.
- Average Operating Leases over 5 years is $11.2 million, with a median of $7.0 million recorded in 2023.
- Peak annual rise in Operating Leases hit 1565.57% in 2025, while the deepest fall reached 73.79% in 2025.
- Year by year, Operating Leases stood at $10.0 million in 2021, then dropped by 23.88% to $7.6 million in 2022, then decreased by 18.06% to $6.2 million in 2023, then plummeted by 52.41% to $3.0 million in 2024, then soared by 1565.57% to $49.3 million in 2025.
- Business Quant data shows Operating Leases for RNA at $49.3 million in Q4 2025, $50.0 million in Q3 2025, and $1.2 million in Q2 2025.